Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI-940 in Advanced or Metastatic Breast Cancer
NCT07408089Phase 1Terminated
- Sponsor
- Boundless Bio
- Start
- Feb 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of BBI-940 in breast cancer (4 arms), sponsored by Boundless Bio. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment Emergent Adverse Events and 1 more. Started Feb 2026; status: terminated.
02
Drugs
BBI-940
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07408089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408089.